FDA approves Risperdal for autistic irritability
The US Food and Drug Administration says that it has approved the antipsychotic agent Risperdal (risperdal), marketed by Johnson & Johnson company Janssen LP, as a treatment for children and adolescents suffering symptomatic irritability associated with autism. The condition includes such behaviors as aggression, deliberate self-injury and temper tantrums.
The agency explained that approval of the drug, which has been available as a short-term treatment for adult schizophrenics since 1993 (Marketletters passim), is the first time an agent has been cleared for use in this very specific and debilitating indication, and added that it will be of benefit to both autistic children and their parents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze